INM - InMed Pharmaceuticals Inc.
3.13
0.030 0.958%
Share volume: 43,000
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.24%
PREVIOUS CLOSE
CHG
CHG%
$3.10
0.06
0.02%
View ratios
| Fiscal Date | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Fiscal Quarter | Q3 2024 | Q4 2024 | Q1 2025 | |
| Report Date | 2024-05-13 | 2024-11-14 | 2024-11-14 | |
| Total revenue | 1.173 M | 1.283 M | 1.265 M | |
| Cost of revenue | 883.143 K | 1.080 M | 771.225 K | |
| Gross profit | 289.458 K | 466.071 K | 493.413 K | |
| 61.02% | 5.87% | |||
| Operating expenses | 2.031 M | 2.420 M | 2.193 M | |
| Selling general and admin | 1.374 M | 1.214 M | 1.422 M | |
| Research and development | 656.764 K | 1.206 M | 771.180 K | |
| Total expenses | 2.086 M | 2.212 M | 2.248 M | |
| 6.04% | 1.63% | |||
| Operating income | -1.796 M | -2.009 M | -1.754 M | |
| Ebit | -1.844 M | -2.034 M | -1.735 M | |
| Pretax income | -1.723 M | -1.931 M | -1.678 M | |
| 12.06% | -13.09% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -1.723 M | -1.938 M | -1.678 M | |
| -12.47% | 13.41% |